Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · November 14, 2021

Apixaban vs No Anticoagulation After Anticoagulation-Associated ICH in Patients With Atrial Fibrillation

The Lancet Neurology

 

Additional Info

The Lancet Neurology
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial
Lancet Neurol 2021 Nov 01;20(11)907-916, FHBM Schreuder, KM van Nieuwenhuizen, J Hofmeijer, SE Vermeer, H Kerkhoff, E Zock, GJ Luijckx, GP Messchendorp, J van Tuijl, HP Bienfait, SJ Booij, IR van den Wijngaard, MJM Remmers, AHCML Schreuder, DW Dippel, J Staals, PJAM Brouwers, MJH Wermer, JM Coutinho, VIH Kwa, IC van Gelder, REG Schutgens, B Zweedijk, A Algra, JW van Dalen, L Jaap Kappelle, GJE Rinkel, HB van der Worp, CJM Klijn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading